STEM-26. SMALL MOLECULE DRUG CBL0137 INHIBITS THE FACT COMPLEX AND SENSITIZES GLIOBLASTOMA CANCER STEM CELLS TO RADIOTHERAPY
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa215.843
Abstract: Glioblastoma (GBM) is a malignant brain tumor with nearly universal recurrence. GBM cancer stem cells (CSCs), a subpopulation of radio- and chemo-resistant cancer cells capable of self-renewal, contribute to the high rate of recurrence. The… read more here.
Keywords: cancer stem; radiotherapy; cbl0137; cancer ... See more keywords
The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-17-1920
Abstract: Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in SCLC, in… read more here.
Keywords: tumor initiating; initiating cells; cbl0137; cancer ... See more keywords
Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
Sign Up to like & getrecommendations! Published in 2023 at "Biomedicines"
DOI: 10.3390/biomedicines11010230
Abstract: The anticancer activity of Curaxin CBL0137, a DNA-binding small molecule with chromatin remodulating effect, has been demonstrated in different cancers. Herein, a comparative evaluation of CBL0137 activity was performed in respect to acute myeloid leukemia… read more here.
Keywords: curaxin cbl0137; aml; features curaxin; targeting features ... See more keywords